ch.oddb.org
 
Apotheken | Hôpital | Interactions | LiMA | Médecin | Médicaments | Services | T. de l'Autorisation
Information professionnelle sur Ezetimib Simvastatin Zentiva®:Helvepharm AG
Information professionnelle complèteDDDAfficher les changementsimprimé 
Composit.Forme gal.Indic./emploiPosolog./mode d'empl.Contre-Ind.PrécautionsInteract.Grossesse
Apt.conduiteEffets indésir.SurdosagePropriétésPharm.cinét.Donn.précl.RemarquesNum. Swissmedic
PrésentationsTitulaireMise à jour 
C10BA02 - Simvastatin and EzetimibeATC-DDD Version 2016. Source: WHO
C - Cardiovascular System

This group comprises substances used for the treatment of cardiovascular conditions.
Drugs used for the treatment of hypertension are classified in C02 - Antihypertensives, C03 - Diuretics, C07 - Beta blocking agents, C08 - Calcium channel blockers, and C09 - Agents acting on the renin-angiotensin system. For the classification of combination products of antihypertensives from different ATC groups, the following ranking should be used, from higher to lower precedence: C09, C07, C08, and C03.

C10 - Lipid Modifying Agents
 

The DDDs are based on the treatment of hypercholesterolemia.

C10B - Lipid Modifying Agents, Combinations

Fixed combinations of blood glucose-lowering drugs and lipid modifying agents are classified in A10B.

For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.

C10BA - Combinations Of Various Lipid Modifying Agents
 

The DDD for the fixed combination of simvastatin or atorvastatin and ezetimibe is 1 UD (1 tablet), regardless of strength.
The DDD for the fixed combination of pravastatin and fenofibrate is 1 UD (1 tablet), regardless of strength.

C10BA02 - Simvastatin and Ezetimibe
2024 ©ywesee GmbH
Einstellungen | Aide | FAQ | Identification | Contact | Home